New Recruiting Trial: Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
WHY IT MATTERS
This trial offers a potential new option for patients with recurrent head and neck squamous cell carcinoma who have limited treatment choices after their cancer returns following initial radiation therapy.
Researchers are testing a new treatment for head and neck cancer that comes back after radiation therapy. The treatment combines radiation therapy again with a drug called chidamide, which helps boost the body's immune system to fight cancer cells. This is an early-stage study (Phase 1) just starting to recruit patients in 2026.
NCT ID: NCT07545967 Title: Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy Status: RECRUITING Phase: PHASE1 Sponsor: West China Hospital Start date: 2026-04-23 URL: https://clinicaltrials.gov/study/NCT07545967 Source: UniteRare clinical trials database